Levemir Flextouch

Insulin detemir, the active ingredient in Levemir Flextouch, is a long‑acting insulin analog presented as a solution for injection for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients and is marketed in the European Union for basal insulin therapy.

GNH USA supplies Levemir Flextouch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows strict quality standards, maintains cold‑chain logistics, and provides regulatory‑approved product for global distribution.

Levemir Flextouch (insulin detemir) provides basal insulin coverage for chronic hyperglycemia in diabetes mellitus.

Type 1 diabetes mellitus: supplies long‑acting basal insulin to maintain fasting glucose levels. Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient to achieve glycemic targets. Diabetes mellitus (general): delivers steady insulin action to reduce overall hyperglycemia and simplify dosing schedules.

Levemir Flextouch may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dose is high. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: rash, urticaria, or anaphylaxis. - Insulin antibodies: formation of antibodies that may alter insulin action.

When using Levemir Flextouch, several precautions should be observed to ensure safe and effective therapy.

Dose adjustment: tailor the dose based on regular blood glucose monitoring and individual response. Renal impairment: monitor kidney function and consider dose reduction as insulin clearance may be decreased. Hepatic impairment: use with caution; liver disease can affect insulin metabolism. Pregnancy: limited data; evaluate risk‑benefit before prescribing to pregnant women. Hypoglycemia risk: educate patients on recognizing symptoms and appropriate treatment measures. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flextouch can interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms, making detection difficult. - MAO inhibitors: can potentiate insulin’s glucose‑lowering action, increasing hypoglycemia risk. - Alcohol: may cause unpredictable glucose fluctuations and enhance hypoglycemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring possible insulin dose adjustment. - Corticosteroids: can increase glucose levels, potentially necessitating higher insulin doses. - Oral hypoglycemics (e.g., sulfonylureas): additive effect on glucose lowering, increasing hypoglycemia risk.